Multiple reports center on criticism of a UK decision-making committee’s stance on prostate cancer screening, with commentary focused on whether current guidance serves people at higher risk. The articles argue that men with a family history—such as having a father or brother who developed or died from prostate cancer—face increased risk compared with the general population. The criticism is directed at the committee that repeatedly declines to endorse widespread screening, and it frames the concern around whether risk-based approaches could be better targeted for men more likely to benefit from earlier detection. The reporting presented the issue in a personal context, referencing family experiences to underline why proponents say screening eligibility and decision-making should account for inherited risk factors. However, the sources provided do not include detailed findings, voting records, or the committee’s stated evidence for declining routine screening. As presented here, the overall coverage reflects an ongoing public dispute about balancing potential benefits of earlier diagnosis against the harms and uncertainties involved in population-wide screening, especially for higher-risk groups.